Holen Sie sich die Stockscreener-App
5.03
3.93%
0.19
Handel nachbörslich:
5.09
0.06
+1.19%
Schlusskurs vom Vortag:
$4.84
Offen:
$4.875
24-Stunden-Volumen:
1.21M
Relative Volume:
1.35
Marktkapitalisierung:
$346.89M
Einnahmen:
$14.20M
Nettoeinkommen (Verlust:
$-49.59M
KGV:
-6.1824
EPS:
-0.8136
Netto-Cashflow:
$-32.86M
1W Leistung:
+2.86%
1M Leistung:
+38.19%
6M Leistung:
+264.49%
1J Leistung:
+440.86%
1-Tages-Spanne:
$4.84
$5.21
1-Wochen-Bereich:
$4.682
$5.30
52-Wochen-Spanne:
$0.65
$5.30
Opus Genetics Inc Stock (IRD) Company Profile
Firmenname
Opus Genetics Inc
Sektor
Branche
Telefon
248-681-9815
Adresse
8 DAVIS DRIVE, DURHAM
Compare IRD vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
5.03 | 333.79M | 14.20M | -49.59M | -32.86M | -0.8136 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-20 | Eingeleitet | BTIG Research | Buy |
| 2025-12-10 | Eingeleitet | B. Riley Securities | Buy |
| 2025-11-25 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-29 | Eingeleitet | Wedbush | Outperform |
| 2025-10-16 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-04-11 | Eingeleitet | Craig Hallum | Buy |
| 2024-11-13 | Fortgesetzt | H.C. Wainwright | Buy |
Alle ansehen
Opus Genetics Inc Aktie (IRD) Neueste Nachrichten
Biotechnology company Opus Genetics Inc recently filed documents with the U.S. Securities and Exchange Commission (SEC) to officially register 7.4 million shares of common stock for secondary market resale. - Bitget
Opus Genetics, Inc. 2025 Annual Report: Gene Therapy Pipeline, Clinical Progress, and Strategic Partnerships in Ophthalmology - Minichart
Viatris-Backed Nyxol Trial Completes Phase 3, Setting Up a Key Night-Vision Catalyst - TipRanks
Opus Genetics (IRD) Target Price Raised by Wedbush Analyst | IRD Stock News - GuruFocus
Chardan Capital Raises Price Target for Opus Genetics (IRD) to $11 | IRD Stock News - GuruFocus
BTIG Raises its Price Target on Opus Genetics, Inc. (IRD) to $12 from $7 and Maintains a Buy Rating - Insider Monkey
Craig-Hallum Maintains Buy on Opus Genetics (IRD) March 2026 - Meyka
Craig-Hallum reiterates Buy on Opus Genetics stock, $9 target - Investing.com
Opus Genetics (IRD) Trailing US$49.6m Loss Reinforces Bearish Profitability Narrative - simplywall.st
Opus Genetics Inc. (IRD) Reports FY25 Earnings - AlphaStreet
Opus Genetics (IRD) Reports $0.80 Q4 Loss Despite 230% Revenue Surge to $14.2M - AlphaStreet
Opus Genetics, Inc. (IRD) Announces Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
Opus Genetics, Inc. (IRD) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Opus Genetics (IRD) Exceeds Revenue Projections and Advances Gen - GuruFocus
Earnings Summary: Opus Genetics Q4 - Benzinga
Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update - The Manila Times
Is Opus Genetics Inc. stock near bottom after declineQuarterly Growth Report & Smart Swing Trading Alerts - Naître et grandir
Market Recap: Can Opus Genetics Inc benefit from deglobalizationQuarterly Investment Review & Stock Portfolio Risk Control - baoquankhu1.vn
RTP firm looks to expand market for eye-drop treatment - The Business Journals
Where Opus Genetics Stands With Analysts - Sahm
Opus Genetics to Present at Upcoming Investor Conferences in March 2026 - The Manila Times
Biotech aiming to prevent blindness to present at three investor events - Stock Titan
Analysts Offer Insights on Healthcare Companies: Amneal Pharmaceuticals (AMRX), Concentra Group Holdings Parent, Inc. (CON) and Opus Genetics (IRD) - The Globe and Mail
Opus Genetics (NASDAQ:IRD) Price Target Raised to $12.00 - MarketBeat
FY2026 EPS Estimates for Opus Genetics Raised by Analyst - MarketBeat
Opus Genetics, Inc. (NASDAQ:IRD) Short Interest Update - MarketBeat
Opus Genetics (NASDAQ:IRD) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Opus Genetics reports early positive data from gene therapy trial By Investing.com - Investing.com Australia
Opus Genetics (IRD) Shares Promising Gene Therapy Results - GuruFocus
Opus Genetics Announces Initial Clinical Data from Phase - GlobeNewswire
Opus Genetics reports early positive data from gene therapy trial - Investing.com Nigeria
Opus Genetics earnings beat, revenue fell short of estimates By Investing.com - Investing.com UK
FDA accepts Opus Genetics’ presbyopia treatment application By Investing.com - Investing.com Australia
FDA accepts sNDA of phentolamine 0.75% for presbyopia - Eyes On Eyecare
FDA accepts Opus Genetics’ presbyopia treatment application - Investing.com Nigeria
Viatris, Opus Genetics Say US FDA Agrees to Review New Drug Application for Potential Eye Condition Treatment - marketscreener.com
Viatris, Opus gain as FDA to review label expansion for eyecare drug - Seeking Alpha
FDA Reviews Opus Genetics' (IRD) New Eye Treatment for Presbyopi - GuruFocus
Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine ... - Caledonian Record
Opus Genetics Announces FDA Acceptance Of Supplemental New Drug Application For Phentolamine Ophthalmic Solution 0.75% For The Treatment Of Presbyopia - TradingView
Opus Genetics Announces FDA Acceptance of Supplemental New - GlobeNewswire
Chipmakers Recap: Can Opus Genetics Inc weather a recessionProduct Launch & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Opus Genetics: Asymmetric Upside With LCA5 And BEST1 (NASDAQ:IRD) - Seeking Alpha
Aug Patterns: Can Ameresco Inc beat the S P 500Weekly Investment Summary & Reliable Price Breakout Signals - baoquankhu1.vn
Opus Genetics (NASDAQ:IRD) Cut to "Sell" at Wall Street Zen - MarketBeat
Opus Genetics (NASDAQ:IRD) Cut to “Sell” at Wall Street Zen - Defense World
Balyasny Asset Management L.P. Acquires Significant Stake in Opu - GuruFocus
Balyasny Asset Management L.P. Acquires Significant Stake in Opus Genetics Inc - GuruFocus
Opus Genetics Closes $25 Million Series B Financing - TipRanks
Opus Genetics Raises $25 Million in Private Placement of Series B Preferred at $3.39 - TradingView
Opus Genetics (NASDAQ: IRD) boosts cash with $25M Series B preferred - Stock Titan
Finanzdaten der Opus Genetics Inc-Aktie (IRD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):